Nycomed / Altana Pharma AG

Gastroesophageal Reflux Disease (GERD)

$1.8B Pantoprazole pre-deal global sales

Disease Overview

GERD is a chronic acid-reflux condition affecting roughly 20% of US adults; PPIs are the standard of care. Pantoprazole (Protonix) was Altana's gastroenterology blockbuster and formed the cash-flow base for the deal, but faced near-term patent erosion that informed Nycomed's diligence price.

Competitive Landscape

The mid-2000s PPI market was a heavyweight branded category dominated by AstraZeneca's Nexium (esomeprazole), Takeda's Prevacid (lansoprazole), Eisai/Janssen's Aciphex (rabeprazole), and AstraZeneca's Prilosec (omeprazole, by then OTC). Altana/Wyeth's Protonix (pantoprazole) was the smaller branded entrant, generating ~$1.8B globally pre-deal but facing US generic entry in 2009 (Teva and Sun launched at-risk generics). The Nycomed deal was therefore priced on a wasting asset; rationale relied on Daxas/Daliresp upside and geographic complementarity (Nycomed Nordic/CEE strength + Altana DACH presence). Per PharmaTimes analyst commentary, Altana sought divestiture because it 'considers it too small to compete on a global stage' against rising R&D costs, and observers split on whether the price was fair given pipeline thinness.

Chronic Obstructive Pulmonary Disease (COPD)

Disease Overview

COPD is a progressive obstructive lung disease driven primarily by smoking and environmental exposures, characterized by chronic bronchitis and/or emphysema. Standard-of-care therapies are inhaled bronchodilators (LABA, LAMA) and corticosteroids; oral PDE-4 inhibition emerged in the 2010s as an option to reduce exacerbations in severe disease.

Competitive Landscape

At the time of the Nycomed-Altana deal (Sept 2006), inhaled therapies dominated COPD: GSK's Advair (fluticasone/salmeterol), Boehringer Ingelheim's Spiriva (tiotropium), and AstraZeneca's Symbicort (budesonide/formoterol). Altana's late-stage candidate Daxas (roflumilast), the first oral PDE-4 inhibitor for COPD, was the strategic prize despite an EMA filing withdrawal in 2005. Nycomed prosecuted the program through EU approval in June 2010 and US FDA approval as Daliresp in February 2011. Altana also brought blockbuster pantoprazole (Protonix), a PPI generating ~$1.8B but facing 2009 patent expiry, plus inhaled corticosteroid Alvesco. Analysts noted Altana had a 'shallow new drug pipeline' over-reliant on pantoprazole, and Nycomed's own historical reliance on in-licensing. The combined entity gained scale (~12,000 employees, €3.1B sales) before Takeda acquired Nycomed in 2011 for ~$14B.